Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation Therapy

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OF ASPIRIN AS ADJUVANT THERAPY FOR NODE POSITIVE HER2 NEGATIVE BREAST CANCER: THE ABC TRIAL.

Intervention/treatment:
ACETYLSALICYLIC ACID
Medical condition:
BREAST CANCER
Protocol code:
A011502 / CCTG MAC.21
Control number:
208448
Status:
Closed
Approved:
September 08, 2017
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02927249
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 69 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Wendy Chen
Organization
Dana Farber Cancer Institute
Phone:
617-632-3800
Sponsor
CANADIAN CANCER TRIALS GROUP, CANCER RESEARCH INSTITUTE, QUEEN'S UNIVERSITY

Locations

Alberta

Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2

British Columbia

BCCA-Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6

New Brunswick

Atlantic Health Sciences Corporation-Saint John Regional Hospital
Saint John, New Brunswick, E2L 4L2
The Vitalite Health Network - Dr Leon Richard Oncology Centre
Moncton, New Brunswick, E1C 8X3

Ontario

Cambridge Memorial Hospital
Cambridge, Ontario, N1R 3G2
Grand River Regional Cancer Centre at Grand River Hospital
Kitchener, Ontario, N2G 1G3
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7
London Regional Cancer Program
London, Ontario, N6A 4L6
Odette Cancer Centre- Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N 3M5

Prince Edward Island

PEI Cancer Treatment Centre-Queen Elizabeth Hospital
Charlottetown, Prince Edward Island, C1A 8T5

Quebec

CIUSSSEMTL-Hopital Maisonneuve-Rosemont
Montreal, Quebec, H1T 2M4

Saskatchewan

Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4

Results

See the results from the trial NCT02927249. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?